Related Experiment Videos
Atenolol and celiprolol for stable angina pectoris
J M McLenachan1, I N Findlay, E Henderson
1Cardiac Department, Western Infirmary, Glasgow, Scotland.
The American Journal of Cardiology
|February 10, 1988
Summary
Both atenolol and celiprolol effectively treat stable angina pectoris by reducing chest pain and cardiac ischemia. Celiprolol may offer additional benefits beyond heart rate reduction for antianginal efficacy.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Stable angina pectoris is a common condition characterized by chest pain due to myocardial ischemia.
- Beta-blockers are a cornerstone therapy for managing angina.
- Novel beta-blockers with potentially different mechanisms are of clinical interest.
Purpose of the Study:
- To compare the efficacy and effects of once-daily atenolol and celiprolol in patients with stable angina pectoris.
- To investigate potential differences in their antianginal mechanisms.
Main Methods:
- A placebo-controlled, crossover study design was employed.
- Sixteen patients with stable angina pectoris participated.
- Outcomes measured included angina frequency, electrocardiographic (ECG) evidence of ischemia, and double product at specific ST-segment depression levels.
Main Results:
- Both atenolol and celiprolol significantly reduced angina frequency and ECG-documented cardiac ischemia compared to placebo.
- Both medications demonstrated equal efficacy in reducing these primary endpoints.
- Celiprolol showed less suppression of the double product at 1 mm ST-segment depression compared to atenolol.
Conclusions:
- Once-daily atenolol and celiprolol are equally effective in reducing angina symptoms and cardiac ischemia.
- Celiprolol's distinct effect on the double product suggests non-heart rate-lowering mechanisms contribute to its antianginal properties.
- Further research into celiprolol's unique pharmacological actions is warranted.